Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2022.Apr.06

AEMPS of Spain revokes previous approval for the Active Cancer Immunotherapy, OBI-822, to proceed to Phase III Clinical Trial

2022.Mar.25

Announcement of the Company's full receipt of cash capital increase in 2022 and the reference date of capital increase

2022.Mar.18

Announcement of not Distributing Dividends in 2021

2022.Mar.18

The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting

2022.Mar.18

Announcement of 2021 Consolidated Financial Statements were approved by the Board of Directors

2022.Mar.17

Supplemental announcement-subscription rights to the cash issue forfeited by directors of the Company reaching 50% and made to specific persons

2022.Mar.17

Subscription rights to the cash issue forfeited by directors of the Company reaching 50% and subscription being made available to specific persons

2022.Mar.17

Announcement of calls on unpaid shares of 2022 cash capital increase

2022.Feb.23

TFDA has granted the approval for the active cancer immunotherapy OBI-833 to proceed to a Phase II clinical trial

2022.Feb.23

Supplementary Statements On News Article

News

Latest News

Events

Latest events